Osivax: Funding, Investors & Team (Sep 2026)
Osivax develops immunotherapy vaccines that aim to simplify the treatment of contagious illnesses. These vaccines enhance the absorption into dendritic cells and enhance the immune response to natural proteins, resulting in a more powerful and unique activation of CD8 T cells. By doing so, doctors can effectively treat patients with cancer, as well as influenza, malaria, and other infectious diseases in a more efficient manner.
Osivax has raised $43.1M across 5 funding rounds on record, the most recent an undisclosed round of $19.5M announced in Aug 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Osivax Company Profile and Key Stats
Latest funding round on record: Aug 2025.
Osivax Funding Rounds
Osivax raised $10.6M in a Grant announced in Jun 2022.
9 months later, an undisclosed round of $1.0M was announced in Mar 2023.
9 months later, an undisclosed round of $1.5M was announced in Dec 2023.
1.3 years later, a Series B of $10.5M was announced in Mar 2025.
5 months later, an undisclosed round of $19.5M was announced in Aug 2025.
Osivax Founders and Leadership Team
Contact details for the Osivax team: 1 of 2 have an email address on file.
Start 14-day free trial →Osivax Funding Compared to Other Biotechnology Startups
Osivax's latest round of $19.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Osivax in Biotechnology and Lyon
Companies Similar to Osivax
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
Osivax Funding FAQs
What does Osivax do?
Osivax develops immunotherapy vaccines that aim to simplify the treatment of contagious illnesses. These vaccines enhance the absorption into dendritic cells and enhance the immune response to natural proteins, resulting in a more powerful and unique activation of CD8 T cells. By doing so, doctors can effectively treat patients with cancer, as well as influenza, malaria, and other infectious diseases in a more efficient manner.
How much funding has Osivax raised?
Osivax has raised $43.1M across 5 rounds on record. The most recent is an undisclosed round of $19.5M announced in Aug 2025.
When did Osivax last raise funding?
Osivax's most recent funding round on record is an undisclosed round of $19.5M, announced in Aug 2025.
Who founded Osivax?
FundedIQ lists Alexandre Le Vert (Founder), Alexandre Levert (Founder) at Osivax.
Where is Osivax headquartered?
Osivax is based in Lyon, Rhone-Alpes, France.
How many employees does Osivax have?
Osivax is in the 51-100 employee band.
How does Osivax's funding compare to other Biotechnology startups?
Osivax's latest round of $19.5M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Osivax Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Osivax is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.